Earnings Summary

Moleculin Biotech, Inc.’s revenue jumped NaN% since last year same period to $0Mn in the Q3 2023. On a quarterly growth basis, Moleculin Biotech, Inc. has generated NaN% jump in its revenue since last 3-months.

Moleculin Biotech, Inc.’s net profit jumped 34.61% since last year same period to $-5.61Mn in the Q3 2023. On a quarterly growth basis, Moleculin Biotech, Inc. has generated 6.14% jump in its net profits since last 3-months.

Moleculin Biotech, Inc.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q3 2023. On a quarterly growth basis, Moleculin Biotech, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Moleculin Biotech, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.24 - a 0% jump from last quarter’s estimates.

Moleculin Biotech, Inc.’s earning per share (EPS) estimates for the current year stand at -0.24.

Moleculin Biotech, Inc.’s earning per share (EPS) jumped 36.67% since last year same period to -0.19 in the Q3 2023. This indicates that the Moleculin Biotech, Inc. has generated 36.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Moleculin Biotech, Inc.’s return on assets (ROA) stands at -0.33.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Moleculin Biotech, Inc.’s return on equity (ROE) stands at -0.56.